Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Empagliflozin on hs-CRP in T2DM
NCT06952231Phase 3Completed
- Sponsor
- The University of Lahore
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sitagliptin, empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The University of Lahore. Started May 2024; status: completed.
02
Drugs
sitagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06952231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952231.